Scholarlink

Background <p>Lysosomal acid lipase deficiency (LAL-D) is an autosomal recessive disorder caused by mutations in the <i>LIPA</i> gene, which results in lipid accumulation leading to multi-organ failure. If left untreated, the severe form of LAL-D results in premature death within the first year of life due to failure to thrive and hepatic insufficiency. Weekly systemic injections of recombinant LAL protein, referred as enzyme replacement therapy, is the only available supportive treatment.</p> Method <p>Here, we characterized a novel <i>Lipa</i><sup><i>−/−</i></sup> mouse model and developed a curative gene therapy treatment based on the in vivo administration of recombinant (r)AAV8 vector encoding the human <i>LIPA</i> transgene under the control of a hepatocyte-specific promoter.</p> Results <p>Here we define the minimal rAAV8 dose required to rescue disease lethality and to correct cholesterol and triglyceride accumulation in multiple organs and blood. Finally, using liver transcriptomic and biochemical analysis, we show mitochondrial impairment in <i>Lipa</i><sup><i>−/−</i></sup> mice and its recovery by gene therapy.</p> Conclusions <p>Overall, our in vivo gene therapy strategy achieves a stable long-term LAL expression sufficient to correct the disease phenotype in the <i>Lipa</i><sup><i>−/−</i></sup> mouse model and offers a new therapeutic option for LAL-D patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rescue of lysosomal acid lipase deficiency in mice by rAAV8 liver gene transfer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月11日

查看全文
  • Marine Laurent,
  • Rim Harb,
  • Christine Jenny,
  • Julie Oustelandt,
  • Simon Jimenez,
  • Jeremie Cosette,
  • Francesca Landini,
  • Aristide Ferrante,
  • Guillaume Corre,
  • Nemanja Vujic,
  • Claudia Piccoli,
  • Anais Brassier,
  • Laetitia Van Wittenberghe,
  • Giuseppe Ronzitti,
  • Dagmar Kratky,
  • Consiglia Pacelli,
  • Mario Amendola

摘要

Background

Lysosomal acid lipase deficiency (LAL-D) is an autosomal recessive disorder caused by mutations in the LIPA gene, which results in lipid accumulation leading to multi-organ failure. If left untreated, the severe form of LAL-D results in premature death within the first year of life due to failure to thrive and hepatic insufficiency. Weekly systemic injections of recombinant LAL protein, referred as enzyme replacement therapy, is the only available supportive treatment.

Method

Here, we characterized a novel Lipa−/− mouse model and developed a curative gene therapy treatment based on the in vivo administration of recombinant (r)AAV8 vector encoding the human LIPA transgene under the control of a hepatocyte-specific promoter.

Results

Here we define the minimal rAAV8 dose required to rescue disease lethality and to correct cholesterol and triglyceride accumulation in multiple organs and blood. Finally, using liver transcriptomic and biochemical analysis, we show mitochondrial impairment in Lipa−/− mice and its recovery by gene therapy.

Conclusions

Overall, our in vivo gene therapy strategy achieves a stable long-term LAL expression sufficient to correct the disease phenotype in the Lipa−/− mouse model and offers a new therapeutic option for LAL-D patients.